Evidence map›Paper›PMID 42836876›Full record

ArticleJournal of molecular modeling2026

Deep learning-guided high-throughput screening and molecular dynamics simulations facilitate the discovery of potential FXIIa inhibitors.

Fengze Cai, Wanjun Chen, Song Xie, Juhong Wu, Yongqi Zhang, Ping Gao, Han Zhang, Jinyu Li

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Fengze Cai *College of Chemistry, Fuzhou University, Fuzhou, 350116, China.
Wanjun Chen *College of Chemistry, Fuzhou University, Fuzhou, 350116, China.
Song XieCollege of Chemistry, Fuzhou University, Fuzhou, 350116, China.
Juhong WuCollege of Chemistry, Fuzhou University, Fuzhou, 350116, China.
Yongqi ZhangCollege of Chemistry, Fuzhou University, Fuzhou, 350116, China.
Ping GaoCollege of Chemistry, Fuzhou University, Fuzhou, 350116, China.
Han ZhangCollege of Chemistry, Fuzhou University, Fuzhou, 350116, China. hzhang9710@163.com.
Jinyu LiCollege of Chemistry, Fuzhou University, Fuzhou, 350116, China. j.li@fzu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextPathological thrombosis is a major cause of cardiovascular and cerebrovascular diseases. Current anticoagulants increase bleeding risk by impairing physiological hemostasis. Because coagulation factor XIIa (FXIIa) drives pathological thrombosis but is dispensable for normal hemostasis, inhibiting FXIIa may offer antithrombotic efficacy with reduced bleeding risk. However, the marked flexibility of its active site hampers the discovery of small-molecule inhibitors. Here, we developed an integrated computational workflow to address this challenge and screened a library of approximately 21 million compounds. Four structurally distinct hits (DR1-DR4) were identified. Microsecond-scale molecular dynamics simulations suggested stable binding of all four compounds to FXIIa, and binding free energy calculations suggested that DR1 and DR3 exhibited more favorable binding free energies than the reference inhibitor 1303. These compounds also showed favorable predicted pharmacokinetic properties, providing structurally distinct hits for FXIIa-targeted anticoagulant discovery.

methodsThe crystal structure of the FXIIa catalytic domain (PDB ID: 6B74) was prepared in PyMOL 3.1, and missing regions were modeled with MODELLER. To capture active-site flexibility, apo-FXIIa was subjected to three independent 1-µs molecular dynamics simulations, and a representative conformation selected by clustering was used for virtual screening. A hierarchical screening workflow was carried out in DrugFlow using KarmaDock for primary screening, CarsiDock for redocking, and RTMScore for rescoring. Drug-likeness and pharmacokinetic properties were predicted with SwissADME. Selected complexes were simulated in Amber18 using ff19SB for the protein, GAFF2 for ligands, OPC water, and AM1-BCC ligand charges, and trajectories were analyzed with CPPTRAJ in AmberTools. Binding free energies were estimated with MMPBSA.py using the MM/GBSA method, with entropy contributions evaluated by normal mode analysis. Structural visualization was performed with PyMOL and Discovery Studio Visualizer 2016.

Indexed as

AnticoagulantsDrug DiscoveryFactor XIIaHigh-Throughput Screening AssaysMolecular Dynamics SimulationBlood ProteinsCatalytic DomainHumansLigandsMolecular Docking SimulationProtein BindingThermodynamicsAnticoagulantsBlood ProteinsFactor XIIafactor XIIa inhibitorLigandsComputer-aided drug discoveryFXIIaInhibitorMolecular dynamics simulationVirtual screening

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.